bis[[3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyrazin-2-yl]amino] oxalate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: bis[[3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyrazin-2-yl]amino] oxalate
• 化学式: C₄₂H₄₀Cl₄F₂N₁₂O₆
• 分子量: 988.6
• InChiKey: QNKZZBRGXJHFHK-FGZHOGPDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.8
• 重原子数：
  66
• 可旋转键数：
  17
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  206
• 氢给体数：
  4
• 氢受体数：
  18

文献信息

• [EN] CRIZOTINIB SOLID DISPERSION<br/>[FR] DISPERSION SOLIDE DE CRIZOTINIB
  申请人：HETERO RESEARCH FOUNDATION

  公开号：WO2014115169A2

  公开（公告）日：2014-07-31

  The present invention provides a compound of crizotinib oxalate salt, process for its preparation and pharmaceutical compositions comprising it. The present invention also provides a novel process for the preparation of crizotinib using novel intermediate. The present invention further provides a process for the purification of crizotinib. The present invention further provides a novel amorphous solid dispersion of crizotinib in combination with a pharmaceutically acceptable carrier, process for its preparation and pharmaceutical compositions comprising it.